Acarbose 50mgTablet
Weight Loss & GLP-1 Agonists

Acarbose 50mg

Acarbose

Alpha-glucosidase inhibitor that delays carbohydrate digestion and reduces postprandial glucose spikes, useful as adjunct therapy in type 2 diabetes and modest weight management. Manufactured by Bayer and Torrent for export.

Strengths

25mg / 50mg / 100mg

Packing

10 tablets/strip

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Acarbose 25mg / 50mg / 100mg
Dosage Form
Tablet
Available Strengths
25mg / 50mg / 100mg
Packing
10 tablets/strip
Route of Administration
Oral, with first bite of each meal
Dosage
Start 25mg three times daily with meals; increase gradually to 50-100mg three times daily based on response and tolerance
Indications
Type 2 diabetes (postprandial glucose control), adjunct to diet for weight management, pre-diabetes
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 30°C
Shelf Life
36 months
Side Effects
Flatulence, diarrhea, abdominal pain, bloating (carbohydrate fermentation in colon)
Precautions
GI side effects improve with continued use; treat hypoglycemia with glucose (not sucrose); avoid in inflammatory bowel disease; liver function monitoring at higher doses

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Retatrutide InjectionInjection

Retatrutide Injection

Retatrutide

Investigational triple incretin receptor agonist (GIP/GLP-1/Glucagon) demonstrating exceptional weight loss exceeding 24% body weight in Phase 2 trials, surpassing all currently approved anti-obesity medications and representing the next generation of metabolic therapies. Supplied by Indian manufacturers for research procurement and supplied to markets where investigational compounds are accessible under physician oversight.

5mg / 10mg / 20mg
Tirzepatide InjectionInjection

Tirzepatide Injection

Tirzepatide

First-in-class dual GIP/GLP-1 receptor agonist (twincretin) demonstrating superior HbA1c reduction and up to 22.5% body weight loss in SURPASS and SURMOUNT trials, outperforming semaglutide across all dose levels in head-to-head studies. Available in six escalating weekly dose strengths as a single-dose auto-injector pen, supplied by Eli Lilly-aligned and Indian generic manufacturers for diabetes and obesity management globally.

2.5mg / 5mg / 7.5mg / 10mg / 12.5mg / 15mg
Semaglutide TabletsTablet

Semaglutide Tablets

Semaglutide

World's first oral GLP-1 receptor agonist (Rybelsus) utilizing SNAC absorption technology to enable gastrointestinal uptake of this large peptide molecule, providing once-daily tablet convenience for type 2 diabetes management with HbA1c reductions comparable to injectable GLP-1 agonists. Supplied in 30-tablet bottles from Novo Nordisk-aligned and Indian manufacturers and exported for diabetes management programs preferring non-injectable therapy.

3mg / 7mg / 14mg

Need bulk pricing for Acarbose 50mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote